Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves Ionis Pharmaceuticals' Zanvastro (zilganersen) as first GFAP-targeting therapy for Alexander disease following Ph3 success
Antisense oligonucleotide, neurological, rare genetic disease, Alexander disease, GFAP protein, ASO - Read more

Menarini Group, Gan & Lee Pharmaceuticals partner on GLP-1 bofanglutide European commercialization, $72M upfront, $771M milestones
Licensing deal, commercialization, GLP-1, metabolic disease, milestone payments, royalties - Read more

C4X Discovery receives $13M milestone from AstraZeneca for NRF2 activator entering Phase I clinic
Licensing deal, small molecule, autoimmune, milestone payments, royalties - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Argo Biopharma reports positive Ph2 results for (BW-20805) targeting plasma prekallikrein in hereditary angioedema
Small interfering RNA, rare disease, hereditary angioedema, plasma prekallikrein, siRNA, prophylaxis - Read more

Superluminal Medicines raises $60M, advancing AI-discovered MC4R drug for rare obesity
AI-driven, rare disease, small molecule, obesity, GPCR - Read more

Dimerix secures A$34M ($24.5M) non-dilutive loan facility to fund kidney disease clinical milestones
Clinical-stage, kidney disease, small molecule, rare disease - Read more

Metagen Therapeutics raises JPY 199M ($1.3M) Series B extension for fecal microbiota transplantation clinical trials
Microbiome therapeutics, fecal microbiota transplantation, gastrointestinal, neurological, clinical-stage - Read more

Truist Securities sees biotech momentum continuing through H1 2026, driven by M&A, IPOs, and regulatory stability
Biotech sector, oncology, small molecule, financial, strategic - Read more

FDA grants Fast Track designation to Liquidia Corporation's YUTREPIA for systemic sclerosis-related Raynaud's phenomenon
Inhaled small molecule, autoimmune, rare disease, regulatory - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA issues warning letter to Fresenius Medical Care over complaint handling and contamination inspection failures
Sterile injectable, renal disease, operational, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here